Samjo Management LLC Makes New Investment in Biodesix, Inc. (NASDAQ:BDSX)

Samjo Management LLC purchased a new position in Biodesix, Inc. (NASDAQ:BDSX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 2,477,400 shares of the company's stock, valued at approximately $3,790,000. Biodesix comprises about 1.4% of Samjo Management LLC's holdings, making the stock its 22nd largest holding. Samjo Management LLC owned about 1.70% of Biodesix at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in Biodesix by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 827,199 shares of the company's stock valued at $1,266,000 after purchasing an additional 22,623 shares during the last quarter. AIGH Capital Management LLC raised its stake in Biodesix by 8.8% during the 4th quarter. AIGH Capital Management LLC now owns 6,179,812 shares of the company's stock valued at $9,455,000 after acquiring an additional 500,000 shares in the last quarter. Perkins Capital Management Inc. boosted its position in Biodesix by 46.3% during the 4th quarter. Perkins Capital Management Inc. now owns 1,060,211 shares of the company's stock worth $1,622,000 after acquiring an additional 335,429 shares during the period. HighTower Advisors LLC grew its stake in shares of Biodesix by 17.1% in the fourth quarter. HighTower Advisors LLC now owns 153,934 shares of the company's stock worth $236,000 after purchasing an additional 22,500 shares in the last quarter. Finally, Stephens Inc. AR bought a new stake in shares of Biodesix during the fourth quarter valued at about $303,000. Institutional investors and hedge funds own 20.96% of the company's stock.

Biodesix Price Performance

Biodesix stock traded up $0.01 during mid-day trading on Thursday, hitting $0.56. The company's stock had a trading volume of 204,629 shares, compared to its average volume of 287,742. The stock has a market capitalization of $81.31 million, a P/E ratio of -1.43 and a beta of 1.17. Biodesix, Inc. has a twelve month low of $0.51 and a twelve month high of $2.04. The stock's fifty day moving average price is $0.80 and its two-hundred day moving average price is $1.21. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30.

Biodesix (NASDAQ:BDSX - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. The business had revenue of $20.43 million during the quarter, compared to analyst estimates of $19.92 million. Research analysts forecast that Biodesix, Inc. will post -0.35 earnings per share for the current year.

Insider Transactions at Biodesix

In other news, CEO Scott Hutton sold 83,660 shares of the company's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total value of $76,967.20. Following the sale, the chief executive officer now owns 701,947 shares of the company's stock, valued at approximately $645,791.24. This represents a 10.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders have sold 128,702 shares of company stock worth $118,406. 69.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Separately, William Blair reissued an "outperform" rating on shares of Biodesix in a research note on Tuesday, March 4th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $2.95.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.